Last Update 25 Jun 26
Fair value Increased 5.40%GH: Future Returns Will Depend On Executing Expanded Screening And Therapy Selection Approvals
Guardant Health’s analyst-derived fair value estimate has shifted higher to about $143 from roughly $136, as analysts factor in recent price target increases tied to FDA approvals for Guardant360 Liquid CDx and G360 CDx, Shield’s inclusion in updated screening guidelines, and what they view as stronger long-term growth and profitability potential for the company’s testing portfolio.
Analyst Commentary
Recent research on Guardant Health points to a cluster of higher price targets and constructive views on its testing portfolio, particularly around Guardant360 Liquid CDx, G360 CDx, and Shield. Analysts are weighing these product milestones, reimbursement developments, and guideline inclusions against execution risks and valuation sensitivity.
Bullish Takeaways
- Bullish analysts highlight multiple FDA approvals, including Guardant360 Liquid CDx and the 740 gene G360 CDx panel, as key factors supporting expectations for expanded test volumes and broader clinical adoption. They view these factors as supportive of higher valuation multiples.
- Several research notes point to what they describe as meaningful average selling price potential, citing the G360 ADLT Medicare rate of US$8,455 per test and expectations for commercial and Medicare Advantage reimbursement that could approach this level. They view this as constructive for revenue quality and gross margin mix.
- Coverage initiations and upgrades reference Guardant Health’s position in therapy selection and metastatic cancer testing. Bullish analysts emphasize a large addressable market and the company’s existing testing assets in therapy selection, residual disease, and screening as important growth pillars.
- The inclusion of Guardant Shield in updated colon cancer screening guidelines is cited as a supportive factor for longer term growth in the screening segment, with some analysts tying this development to their higher price targets and expectations for improved test adoption over time.
Bearish Takeaways
- Bearish analysts who have trimmed or tempered price targets in earlier periods highlight execution risk around scaling multiple product lines at once. They suggest that the path from approvals and guideline wins to consistent revenue and profitability may be uneven.
- Some research commentary implies that current valuation already reflects a significant amount of future test adoption and pricing strength. This could make the stock sensitive if volumes, reimbursement negotiations, or new product launches progress more slowly than bullish scenarios assume.
- There is caution that reimbursement dynamics, including how quickly commercial and Medicare Advantage rates align with the new Medicare benchmark for G360 CDx, could influence actual realized pricing and margin outcomes relative to optimistic expectations.
- Analysts also flag timing risk around new product launches such as tumor informed residual disease testing and further Shield uptake. Any delays or slower than expected uptake could affect near to medium term growth trajectories that support current fair value estimates.
What’s in the News for Guardant Health
- Goldman Sachs, Wolfe Research, and RBC Capital Markets initiated coverage on Guardant Health with Buy or Outperform ratings and price targets between US$150 and US$165, citing growth drivers such as the FDA approved G360 CDx 740 gene panel and a path that analysts describe toward potential free cash flow breakeven by 2027, while also noting insider sales of about US$41.2 million in recent months as a point for investors to watch. (Source: Goldman Sachs, Wolfe Research, RBC Capital Markets coverage summary)
- The U.S. FDA approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS, the first targeted therapy for adults with HER2 mutant advanced non small cell lung cancer. This marks the 27th companion diagnostic indication for Guardant360 CDx across tumor types and reinforces Guardant Health’s role in liquid biopsy based cancer testing. (Source: FDA approval announcement)
- Guardant Health’s FDA approved Shield blood test was added to updated American Cancer Society colorectal cancer screening guidelines as an option for average risk adults age 45 and older who decline or have not completed stool based or visual exams, with ACS highlighting Shield’s high completion rates in real world use and its potential to reach unscreened populations. (Source: American Cancer Society guideline update)
- The FDA cleared Guardant360 Liquid CDx, Guardant Health’s expanded liquid biopsy panel that integrates genomic and epigenomic profiling on its Smart Platform, transferring seven prior companion diagnostic indications from Guardant360 CDx and positioning the test as a broad, blood based option for comprehensive tumor profiling covered by Medicare and commercial insurers. (Source: Guardant360 Liquid CDx product announcement)
- Guardant Health raised its full year 2026 revenue guidance to a range of US$1.30b to US$1.32b, compared with a prior range of US$1.25b to US$1.28b, and announced additional FDA approvals for Guardant360 CDx in advanced breast cancer, as well as a multi year collaboration with Nuvalent to support oncology drug development and potential companion diagnostics using Guardant Infinity tests. (Source: company guidance update and partnership announcements)
Valuation Changes for Guardant Health
- Fair Value: The analyst-derived fair value estimate for Guardant Health has risen slightly from about $135.76 to about $143.09.
- Discount Rate: The discount rate assumption is essentially unchanged, holding around 7.11%.
- Revenue Growth: The modeled revenue growth rate has moved slightly higher from roughly 29.22% to about 29.97%.
- Profit Margin: The long-term profit margin assumption has risen meaningfully from about 18.76% to roughly 29.24%.
- Future P/E: The future P/E multiple used in the analysis has fallen significantly from about 6,066.58x to roughly 4,031.72x.
6 viewsusers have viewed this narrative update
Key Takeaways
- Strong demand for blood-based cancer diagnostics and integration of advanced analytics are driving rapid revenue growth, market expansion, and higher product margins.
- Clinical validation, regulatory wins, and operational efficiencies are improving reimbursement prospects and accelerating the company's path to profitability.
- Persistent high spending, reimbursement risks, intensifying competition, and uncertain payer adoption threaten Guardant Health's path to profitability and sustained revenue growth.
Catalysts
About Guardant Health- A precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
- Accelerating adoption of non-invasive blood-based cancer diagnostics is driving substantial growth across Guardant Health's key product lines (Guardant360 Liquid, Reveal, and Shield), expanding the company's total addressable market and supporting high double-digit revenue growth, with continued strong volume momentum and share gains documented for both new and established oncology applications.
- Demographic and healthcare shifts, especially the aging population and rising global cancer incidence, are triggering sustained demand for early detection and personalized oncology solutions like Guardant Health's liquid biopsy and multi-cancer detection platforms-positioning the company for durable, long-term topline expansion.
- Rapid integration of AI-powered clinical analytics and multi-omic profiling into Guardant's "Smart Liquid Biopsy" platform is creating new clinical applications, enhancing product utility and differentiation versus peers, which is leading to higher average selling prices (ASPs), rising margins, and increased potential for broader payer reimbursement and improved net margins.
- Substantial regulatory, reimbursement, and clinical validation milestones (including Shield's breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption, expanded payer coverage, and commercial inflections in Shield/MCED and Reveal volumes-significantly increasing future revenue and earnings visibility.
- Significant improvements in operational scale-evidenced by material reductions in cost of goods sold and sharply improving gross margins in both Shield and Reveal-are fueling operating leverage, accelerating the path toward profitability and cash flow breakeven, and enhancing long-term margin expansion as test volumes scale.
Guardant Health Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Guardant Health's revenue will grow by 30.0% annually over the next 3 years.
- Analysts assume that profit margins will increase from -40.1% today to 0.3% in 3 years time.
- Analysts expect earnings to reach $6.9 million (and earnings per share of -$0.14) by about June 2029, up from -$433.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $144.4 million in earnings, and the most bearish expecting $-233.1 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 4042.1x on those 2029 earnings, up from -41.9x today. This future PE is greater than the current PE for the US Healthcare industry at 23.6x.
- Analysts expect the number of shares outstanding to grow by 6.33% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Ongoing high R&D and SG&A expenses, paired with continued net losses and substantial cash burn (e.g., free cash flow burn targeted at ~$225-235 million for 2025 and sustained $200 million/year toward Shield), increase the risk Guardant Health may not reach profitability as projected, possibly leading to future equity dilution or unfavorable debt, negatively impacting earnings and shareholder value.
- Reliance on further commercial payer adoption and guideline inclusion for Shield (particularly from ACS, USPSTF, and major private insurers) means failure or delays in broadening coverage could limit Shield's revenue growth, especially as management expects payer mix to shift and ASPs (average selling prices) may decrease in 2026, directly pressuring topline growth and margins.
- Intensifying competition from established diagnostics giants and new entrants in liquid biopsy-some of whom may deliver superior or lower-cost technologies-poses a threat to Guardant's market share, pricing power, and revenue growth, while the company's heavy investments in innovation could outpace market adoption.
- Policy and reimbursement uncertainty, including the pending impact of changes or delays in Medicare, commercial coverage, and potential reimbursement cuts or scrutiny by regulatory panels (e.g., reshuffling of USPSTF, variability in ADLT status outcomes), could hinder clinical adoption rates of new tests and affect both revenue and net margins.
- Economic pressures such as persistent inflation, higher interest rates, or macroeconomic stagnation could reduce healthcare expenditure, tightening hospital and insurer budgets and slowing the uptake of premium diagnostic tests-this would further hurt revenue growth and delay positive earnings inflection.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $143.09 for Guardant Health based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $190.0, and the most bearish reporting a price target of just $90.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.4 billion, earnings will come to $6.9 million, and it would be trading on a PE ratio of 4042.1x, assuming you use a discount rate of 7.1%.
- Given the current share price of $136.96, the analyst price target of $143.09 is 4.3% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Guardant Health?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
US$82.18
FV
104.4% overvalued intrinsic discount31
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$140
FV
20.0% overvalued intrinsic discount33
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative